Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more …
General Meeting of Shareholders (GM) to be held on October 28, 2026
NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON OCTOBER 28, 2026 (CLICK TO VIEW AND DOWNLOAD) PROXY FORM (CLICK TO VIEW AND DOWNLOAD) …
[Read more...] about General Meeting of Shareholders (GM) to be held on October 28, 2026
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism Expands …
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in …
Akari Therapeutics Participates in the Virtual Investor “Why Now” On-Demand Conference
Video webcast now available here TAMPA, FL and LONDON – August 27, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company …
